IS6426A - Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni - Google Patents

Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni

Info

Publication number
IS6426A
IS6426A IS6426A IS6426A IS6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A
Authority
IS
Iceland
Prior art keywords
piperazinomethylbenzamide
delta
receptor agonist
opioid receptor
compounds
Prior art date
Application number
IS6426A
Other languages
English (en)
Other versions
IS2143B (is
Inventor
Brown William
Walpole Christopher
Plobeck Niklas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6426A publication Critical patent/IS6426A/is
Publication of IS2143B publication Critical patent/IS2143B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)
  • Furan Compounds (AREA)
IS6426A 1999-12-20 2002-06-18 Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni IS2143B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904674A SE9904674D0 (sv) 1999-12-20 1999-12-20 Novel compounds
PCT/SE2000/002562 WO2001046174A1 (en) 1999-12-20 2000-12-15 Novel compounds

Publications (2)

Publication Number Publication Date
IS6426A true IS6426A (is) 2002-06-18
IS2143B IS2143B (is) 2006-09-15

Family

ID=20418210

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6426A IS2143B (is) 1999-12-20 2002-06-18 Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni

Country Status (31)

Country Link
US (2) US6680318B2 (is)
EP (1) EP1242410B1 (is)
JP (1) JP2003522741A (is)
KR (2) KR20070090050A (is)
CN (1) CN1608064A (is)
AT (1) ATE275143T1 (is)
AU (1) AU780799B2 (is)
BG (1) BG65457B1 (is)
BR (1) BR0016591A (is)
CA (1) CA2395300A1 (is)
CZ (1) CZ20022124A3 (is)
DE (1) DE60013486T2 (is)
DK (1) DK1242410T3 (is)
EE (1) EE200200337A (is)
ES (1) ES2225289T3 (is)
HK (1) HK1048308B (is)
HU (1) HUP0300020A3 (is)
IL (2) IL150125A0 (is)
IS (1) IS2143B (is)
MX (1) MXPA02006063A (is)
NO (1) NO322432B1 (is)
NZ (1) NZ519986A (is)
PL (1) PL356780A1 (is)
PT (1) PT1242410E (is)
RU (1) RU2258703C2 (is)
SE (1) SE9904674D0 (is)
SI (1) SI1242410T1 (is)
SK (1) SK8832002A3 (is)
UA (1) UA71650C2 (is)
WO (1) WO2001046174A1 (is)
ZA (1) ZA200204255B (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
WO2002094794A1 (en) 2001-05-18 2002-11-28 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
JP4892654B2 (ja) * 2001-10-29 2012-03-07 マウント クック ファーマ，インコーポレーテッド デルタレセプターアゴニスト化合物によるうつ病の治療方法
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
KR101234421B1 (ko) * 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
US20080262229A1 (en) * 2005-02-28 2008-10-23 Astrazeneca Ab Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH583713A5 (is) 1973-06-29 1977-01-14 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
AU632888B2 (en) 1989-11-22 1993-01-14 Janssen Pharmaceutica N.V. Use of piperazine acetamide derivatives against reperfusion damage
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
ATE195733T1 (de) 1993-07-30 2000-09-15 Delta Pharmaceuticals Inc Als heilmittel nutzbare piperazin verbindungen
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US5693843A (en) * 1995-12-22 1997-12-02 E. I. Du Pont De Nemours And Company Process for hydrocyanation of diolefins and isomerization of nonconjugated 2 alkyl-3-monoalkenenitriles
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
JP4754068B2 (ja) 1997-12-24 2011-08-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds

Also Published As

Publication number Publication date
SE9904674D0 (sv) 1999-12-20
EP1242410B1 (en) 2004-09-01
KR20070090050A (ko) 2007-09-04
ES2225289T3 (es) 2005-03-16
RU2258703C2 (ru) 2005-08-20
HK1048308B (en) 2005-04-08
KR100769814B1 (ko) 2007-10-23
WO2001046174A1 (en) 2001-06-28
NO322432B1 (no) 2006-10-02
RU2002114343A (ru) 2004-01-10
ATE275143T1 (de) 2004-09-15
BR0016591A (pt) 2002-09-10
ZA200204255B (en) 2003-08-28
EP1242410A1 (en) 2002-09-25
UA71650C2 (uk) 2004-12-15
PL356780A1 (en) 2004-07-12
DE60013486T2 (de) 2005-11-17
US20030105110A1 (en) 2003-06-05
BG65457B1 (bg) 2008-08-29
PT1242410E (pt) 2004-12-31
SI1242410T1 (en) 2004-12-31
NO20022920D0 (no) 2002-06-18
AU2418401A (en) 2001-07-03
IS2143B (is) 2006-09-15
IL150125A (en) 2006-08-20
US20040138225A1 (en) 2004-07-15
EE200200337A (et) 2003-10-15
MXPA02006063A (es) 2003-02-06
NO20022920L (no) 2002-07-22
CN1608064A (zh) 2005-04-20
HUP0300020A3 (en) 2005-02-28
HUP0300020A2 (en) 2003-05-28
IL150125A0 (en) 2002-12-01
HK1048308A1 (en) 2003-03-28
DK1242410T3 (da) 2004-11-29
CZ20022124A3 (cs) 2002-11-13
US6680318B2 (en) 2004-01-20
KR20020062350A (ko) 2002-07-25
DE60013486D1 (de) 2004-10-07
AU780799B2 (en) 2005-04-21
CA2395300A1 (en) 2001-06-28
JP2003522741A (ja) 2003-07-29
NZ519986A (en) 2004-06-25
SK8832002A3 (en) 2003-03-04
BG106805A (en) 2003-03-31

Similar Documents

Publication Publication Date Title
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
DK1193270T3 (da) Pyrrolobenzodiazepiner
DE69819311D1 (de) Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EE200100243A (et) 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks
BR9910908A (pt) Indenopirrolocarbazóis ligados em ponte
IT1285770B1 (it) Composti corticoidei
ATE332903T1 (de) Kondensierte pyridoindolderivate
ATE326209T1 (de) Verminderung des haarwuchses
CO5271666A1 (es) Derivados de pirimidina
SI1181294T1 (en) Novel derivatives and analogues of galanthamin
PL340467A1 (en) Application of mithrazapin in treating apnoea dissomnia
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
DE60112960D1 (de) Kondensierte pyridoindolderivate
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
BG105847A (en) Calcilytic compounds
DE60008400D1 (de) Triazolopyrimidinderivate
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine